Почетна › Рак дојке › Ilinois › Chicago
Kliničke studije za Рак дојке u gradu Chicago, IL
59 studija za Рак дојке traži učesnike na lokacijama u gradu Chicago i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Тражи се учесникФаза 1
- University of Illinois at Chicago, Chicago
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Тражи се учесникФаза 3
- John H Stroger Jr Hospital of Cook County, Chicago
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Тражи се учесникФаза 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Тражи се учесникФаза 2
- University of Illinois Cancer Center, Chicago
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Тражи се учесникФаза 4
- University of Illinois, Chicago
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Тражи се учесник
- Northwestern University, Chicago
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Тражи се учесникФаза 1/2
- Northwestern University, Chicago
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Тражи се учесникФаза 3
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Тражи се учесникФаза 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
E-Mindfulness Approaches for Living After Breast Cancer
Тражи се учесникФаза 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Swedish Covenant Hospital, Chicago
- и још 1
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Тражи се учесникФаза 2
- City of Hope, Chicago, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- и још 1
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Тражи се учесникОпсервациона студија
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Тражи се учесникФаза 3
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- и још 5
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Тражи се учесникФаза 2
- The University of Chicago Medical Center, Chicago
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Тражи се учесникОпсервациона студија
- Rush Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 2
- University of Illinois Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Тражи се учесникФаза 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Тражи се учесникФаза 3
- Rush University Medical Center ( Site 0079), Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Тражи се учесникФаза 1/2
- Research Site, Chicago
A Study of PHST001 in Advanced Solid Tumors
Тражи се учесникФаза 1
- University of Chicago Medical Center, Chicago
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Тражи се учесникФаза 2
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Тражи се учесникФаза 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
Тражи се учесник
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Тражи се учесникФаза 3
- Research Site, Chicago
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Тражи се учесникЗдраве особе су добродошле
- University of Chicago, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Тражи се учесникФаза 1
- University of Chicago, Chicago
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Тражи се учесникФаза 2
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Тражи се учесникФаза 2
- University of Illinois Cancer Center, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Тражи се учесникФаза 3
- Northwestern University, Chicago
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
Тражи се учесникЗдраве особе су добродошле
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Тражи се учесникФаза 2
- University of Chicago Medical Center, Chicago
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Тражи се учесникФаза 2
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
Тражи се учесникФаза 2
- University of Illinois, Chicago
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Тражи се учесникФаза 2
- The University of Chicago Medical Center, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Тражи се учесникФаза 3
- Northwestern University, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Тражи се учесникФаза 2/3
- Local Institution - 0280, Chicago
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Тражи се учесникФаза 3
- Northwestern University - Northwestern Memorial Hospital, Chicago
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Тражи се учесникФаза 2
- Northwestern University, Chicago
- University of Illinois College of Medicine - Chicago, Chicago
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Тражи се учесникФаза 2
- Northwestern University, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Тражи се учесникФаза 1/2
- Northwestern University, Chicago
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Тражи се учесникФаза 1
- University of Chicago Comprehensive Cancer Center, Chicago
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Тражи се учесникФаза 2
- Northwestern University, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Тражи се учесникФаза 2
- University of Chicago, Chicago
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
Тражи се учесник
- Robert H. Lurie Comprehensive Cancer Center, Chicago
- University of Illinois Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Тражи се учесникФаза 2
- University of Chicago Medical Center, Chicago
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Тражи се учесникФаза 3
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- Rush MD Anderson Cancer Center, Chicago
- и још 2
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Тражи се учесникФаза 1
- Northwestern Memorial Hospital, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Тражи се учесникФаза 1/2
- University of Chicago Medical Center, Chicago
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
Тражи се учесник
- University of Illinois, Chicago
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Тражи се учесникФаза 2
- University of Chicago Medical Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Тражи се учесникФаза 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Тражи се учесникФаза 4
- University of Chicago Medical Center, Chicago
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
Тражи се учесникФаза 2
- University of Illinois, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Chicago
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
Тражи се учесникОпсервациона студија
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Тражи се учесникФаза 1
- University of Chicago Medical Center, Chicago
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Тражи се учесникОпсервациона студија
- University of Illinois at Chicago, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Studije za Рак дојке u drugim gradovima
- New York City, NY144 студија
- Houston, TX126 студија
- Boston, MA110 студија
- Nashville, TN78 студија
- Los Angeles, CA73 студија
- Edison, NJ70 студија
- Queens, NY67 студија
- Durham, NC63 студија
- St. Louis, MO63 студија
- Dallas, TX54 студија
- Philadelphia, PA51 студија
- Arlington, VA50 студија
Ostale studije u gradu Chicago
- Немалоклетни карцином плућа59 студија
- Рак (све врсте)51 студија
- Рак простате45 студија
- Рак плућа43 студија
- Метастатски карцином42 студија
- Гојазност40 студија
- Рак јајника36 студија
- Колоректални карцином32 студија
- Шлог31 студија
- Плоскоклеточни карцином главе и врата29 студија
- Гојазност29 студија
- Затајење срца28 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.